Aller au contenu. | Aller à la navigation

Outils personnels

  • Le CIRI sur Linkedin
Navigation

Tutelles

logo Inserm      logo cnrslogo ENSL       logo ucb1


Tutelles secondaires

logo ENSL logo ucb1

Vous êtes ici : Accueil / Équipes / Paul S - GIMAP / Actualités / Association of IFNAR1 and IFNAR2 with COVID-19 severity

Association of IFNAR1 and IFNAR2 with COVID-19 severity

The Lancet Microbe: Yaugel-Novoa M., Bourlet T., Longet S., Botehlo-Nevers E, Paul S. https://www.thelancet.com/journals/lanmic/article/PIIS2666-5247(23)00095-2/fulltext

Type I interferons propagate and amplify the antiviral response at the start of an infection and are crucial for effective antiviral immunity. Type I interferons bind interferon alpha/beta receptors 1 (IFNAR1) and 2 (IFNAR2), which are ubiquitous, but expressed differentially depending on the cell type.

Our study suggest that serum IFNAR1 and IFNAR2 concentrations in patients with COVID-19 can be used as predictors of disease severity and response to interferon treatment outcomes.

Mots-clés associés :
Paul S - GIMAP